Safe Prescribing — MCQs
On this page
A 42-year-old woman with type 2 diabetes on insulin presents to the emergency department following accidental administration of 50 units of rapid-acting insulin (insulin aspart) instead of her usual 10 units. This was given 30 minutes ago. Her current blood glucose is 8.2mmol/L and she is asymptomatic. What is the most appropriate immediate management strategy?
A 65-year-old woman with mechanical mitral valve replacement is on warfarin with target INR 2.5-3.5. She is scheduled for dental extraction in 2 weeks. Her current INR is 3.0. What is the most appropriate peri-procedural anticoagulation management?
A 28-year-old man with newly diagnosed epilepsy is started on sodium valproate. What is the single most important baseline investigation that must be performed before starting sodium valproate?
A 82-year-old woman with atrial fibrillation is on warfarin with stable INR of 2.5. She develops a urinary tract infection and the GP prescribes a 7-day course of antibiotics. Which antibiotic would be most likely to significantly increase her INR?
A 76-year-old man is prescribed lithium carbonate for bipolar affective disorder. Which of the following is the most appropriate monitoring schedule for lithium therapy?
A 34-year-old woman with type 1 diabetes is 10 weeks pregnant. She is currently on a basal-bolus insulin regimen with insulin glargine 20 units at night and insulin aspart with meals. Her HbA1c is 7.8% (62mmol/mol). What is the most appropriate modification to her diabetes management?
A 58-year-old man is started on direct oral anticoagulant (DOAC) therapy following a diagnosis of atrial fibrillation. His CHA₂DS₂-VASc score is 3. He has normal renal function (eGFR 78ml/min/1.73m²) and normal liver function. Which of the following statements about DOAC monitoring is correct?
A 55-year-old woman with rheumatoid arthritis on methotrexate 15mg weekly presents to the emergency department with a 3-day history of mouth ulcers, sore throat, and fever. Her full blood count shows: Hb 118g/L, WCC 1.2×10⁹/L, neutrophils 0.3×10⁹/L, platelets 245×10⁹/L. What is the most critical immediate action?
A 72-year-old man is started on digoxin for rate control in atrial fibrillation. Which of the following factors would require a dose reduction of digoxin?
A 45-year-old woman with type 1 diabetes mellitus is admitted with diabetic ketoacidosis. After initial resuscitation with intravenous fluids and insulin infusion, her blood glucose drops from 28mmol/L to 14mmol/L within 2 hours. Her pH is 7.18 and ketones remain elevated at 4.2mmol/L. What is the most appropriate next step in insulin management?
Safe Prescribing UK Medical PG Practice Questions and MCQs
Question 231: A 42-year-old woman with type 2 diabetes on insulin presents to the emergency department following accidental administration of 50 units of rapid-acting insulin (insulin aspart) instead of her usual 10 units. This was given 30 minutes ago. Her current blood glucose is 8.2mmol/L and she is asymptomatic. What is the most appropriate immediate management strategy?
- A. Administer 50ml of 50% glucose intravenously immediately
- B. Observe for 2 hours with blood glucose monitoring every 15 minutes and treat hypoglycemia if it develops
- C. Give 100ml of 20% glucose intravenously followed by 10% glucose infusion with close monitoring for at least 12 hours (Correct Answer)
- D. Administer intramuscular glucagon 1mg and discharge with advice
- E. Give oral glucose 20g and recheck blood glucose in 15 minutes
Explanation: ***Give 100ml of 20% glucose intravenously followed by 10% glucose infusion with close monitoring for at least 12 hours*** - This represents a significant **insulin overdose**; since rapid-acting insulin peaks within 1-3 hours, proactive **intravenous glucose** is required to prevent severe, life-threatening hypoglycemia. - A 10% or 20% dextrose infusion provides a steady supply of glucose, and monitoring for **at least 12 hours** is necessary to ensure the pharmacological effect of the large insulin dose has fully dissipated. *Administer 50ml of 50% glucose intravenously immediately* - **50% dextrose** is highly hypertonic, irritating to veins (thrombophlebitis risk), and is generally reserved for patients in an actual **hypoglycemic coma**. - Administering it while the patient is currently **normoglycemic** (8.2 mmol/L) could cause unnecessary **rebound hyperglycemia** and does not provide the sustained coverage needed for an overdose. *Observe for 2 hours with blood glucose monitoring every 15 minutes and treat hypoglycemia if it develops* - A **2-hour observation** is insufficient because the metabolic effects and potential hypoglycemia from a 50-unit insulin aspart overdose can persist beyond this window. - Waiting for **neuroglycopenia** or symptomatic hypoglycemia to develop before acting is unsafe in the context of a known massive **medication error**. *Administer intramuscular glucagon 1mg and discharge with advice* - **Glucagon** has a very short duration of action and is often less effective in **Type 2 Diabetes** patients who may have depleted glycogen stores. - Discharge is contraindicated; significant insulin overdoses require **inpatient admission** due to the high risk of delayed, severe hypoglycemia. *Give oral glucose 20g and recheck blood glucose in 15 minutes* - While **oral glucose** is used for mild, symptomatic hypoglycemia, it is insufficient to counteract the potent, sustained glucose-lowering effect of a **5-fold insulin overdose**. - Relying solely on oral intake risks a sudden drop in consciousness, which would then necessitate **unprotected airway** management and emergency IV access.
Question 232: A 65-year-old woman with mechanical mitral valve replacement is on warfarin with target INR 2.5-3.5. She is scheduled for dental extraction in 2 weeks. Her current INR is 3.0. What is the most appropriate peri-procedural anticoagulation management?
- A. Continue warfarin without interruption as dental procedures are low-bleeding risk (Correct Answer)
- B. Stop warfarin 5 days before procedure, bridge with therapeutic LMWH, restart warfarin post-procedure
- C. Stop warfarin 3 days before procedure, no bridging required, restart warfarin evening of procedure
- D. Switch to DOAC 2 weeks before procedure for easier management
- E. Stop warfarin 5 days before, start IV heparin infusion, stop 4 hours before procedure
Explanation: ***Continue warfarin without interruption as dental procedures are low-bleeding risk***- Dental extractions are considered **low-bleeding risk** procedures, and the risk of **thromboembolism** from stopping anticoagulation in a patient with a mechanical mitral valve outweighs the risk of minor local hemorrhage.- Guidelines recommend continuing **warfarin** if the **INR is within the therapeutic range** (typically <3.5 or 4.0), and using local hemostatic measures like **tranexamic acid** mouthwash or suturing to manage any minor bleeding. *Stop warfarin 5 days before procedure, bridge with therapeutic LMWH, restart warfarin post-procedure* - **Bridging anticoagulation** with low molecular weight heparin (LMWH) is not required for **minor dental procedures** and significantly increases the risk of **post-operative bleeding** without providing additional thrombotic protection. - While the patient has a **mechanical mitral valve** (high thrombotic risk), the low-bleeding-risk nature of the procedure means routine interruption and bridging are unnecessary and potentially harmful. *Stop warfarin 3 days before procedure, no bridging required, restart warfarin evening of procedure* - Stopping **warfarin** for 3 days without any bridging in a patient with a **mechanical mitral valve** exposes them to a high risk of **valve thrombosis** and systemic **embolism** due to an extended period of subtherapeutic anticoagulation. - This approach is inappropriate as it creates a significant **anticoagulation gap** for a patient at high thrombotic risk, without sufficient justification given the procedure's low bleeding risk. *Switch to DOAC 2 weeks before procedure for easier management* - **Direct Oral Anticoagulants (DOACs)** are **contraindicated** in patients with **mechanical prosthetic heart valves** due to an increased risk of thromboembolic events and valve thrombosis. - Patients with mechanical valves must remain on **Vitamin K Antagonists** like warfarin for life-long anticoagulation. *Stop warfarin 5 days before, start IV heparin infusion, stop 4 hours before procedure* - **IV heparin bridging** is reserved for high-thrombotic-risk patients undergoing **major surgical procedures** with high bleeding risk, not for low-bleeding-risk minor dental work. - This strategy is excessively invasive, carries its own risks (e.g., heparin-induced thrombocytopenia), and increases the complexity and **cost of care** unnecessarily for a simple dental extraction.
Question 233: A 28-year-old man with newly diagnosed epilepsy is started on sodium valproate. What is the single most important baseline investigation that must be performed before starting sodium valproate?
- A. Serum ammonia levels
- B. Genetic testing for mitochondrial disorders
- C. Electroencephalogram (EEG)
- D. Full blood count and liver function tests (Correct Answer)
- E. Pregnancy test if female of childbearing potential
Explanation: ***Full blood count and liver function tests*** - **Sodium valproate** is associated with rare but severe **hepatotoxicity**, making baseline **liver function tests (LFTs)** mandatory to identify pre-existing hepatic disease. - It can also cause **thrombocytopenia** and other blood dyscrasias, necessitating a baseline **Full Blood Count (FBC)** for subsequent monitoring. *Serum ammonia levels* - **Hyperammonemia** is a known side effect of valproate, but levels are typically only measured if the patient develops signs of **encephalopathy**. - It is not a standard baseline investigation as it does not reliably predict the development of future **valproate-induced toxicity**. *Electroencephalogram (EEG)* - An **EEG** is vital for the **diagnosis and classification** of epilepsy syndromes, but it is not a safety-related prerequisite for starting medication. - The decision to treat is based on clinical diagnosis; the EEG helps guide drug choice but does not monitor for **drug adverse effects**. *Pregnancy test if female of childbearing potential* - While the **Valproate Pregnancy Prevention Programme** makes this crucial for females due to **teratogenicity**, the patient in this scenario is a **28-year-old man**. - For a male patient, this investigation is irrelevant and does not form part of his mandatory **pre-treatment safety screening**. *Genetic testing for mitochondrial disorders* - This is indicated primarily in children with suspected **Alpers-Huttenlocher syndrome** due to the high risk of **acute liver failure** with valproate. - It is not a routine baseline requirement for an **adult male** unless there is a specific family history or clinical suspicion of a **mitochondrial disorder**.
Question 234: A 82-year-old woman with atrial fibrillation is on warfarin with stable INR of 2.5. She develops a urinary tract infection and the GP prescribes a 7-day course of antibiotics. Which antibiotic would be most likely to significantly increase her INR?
- A. Nitrofurantoin 100mg twice daily
- B. Trimethoprim 200mg twice daily (Correct Answer)
- C. Cefalexin 500mg three times daily
- D. Amoxicillin 500mg three times daily
- E. Fosfomycin 3g single dose
Explanation: ***Trimethoprim 200mg twice daily*** - **Trimethoprim** is a potent inhibitor of the **CYP2C9** enzyme, which is primarily responsible for the metabolism of **S-warfarin**, the more active isomer. - This inhibition significantly reduces **warfarin clearance**, leading to a rapid and substantial increase in **INR** and a high risk of bleeding. *Nitrofurantoin 100mg twice daily* - **Nitrofurantoin** has minimal interaction with the cytochrome P450 system and is not known to inhibit warfarin metabolism. - It is generally considered a **safer antibiotic** choice for patients on warfarin, with a low risk of significant INR fluctuations. *Cefalexin 500mg three times daily* - **Cefalexin**, a **cephalosporin**, does not inhibit the enzymes responsible for warfarin metabolism and usually has a **negligible effect** on INR. - Significant clinical interactions are rare unless a patient has a severe pre-existing **vitamin K deficiency**. *Amoxicillin 500mg three times daily* - **Amoxicillin** is not a known enzyme inhibitor and does not significantly interfere with the **pharmacokinetics** of warfarin. - It is frequently used for infections in warfarinized patients with **stable INR** profiles and typically requires no dose adjustments. *Fosfomycin 3g single dose* - A single dose of **fosfomycin** has a very short duration of action and no known interaction with the **cytochrome P450 system**. - Its lack of systemic metabolic interference makes it an **excellent alternative** for treating uncomplicated UTIs in patients on therapeutic anticoagulation.
Question 235: A 76-year-old man is prescribed lithium carbonate for bipolar affective disorder. Which of the following is the most appropriate monitoring schedule for lithium therapy?
- A. Lithium levels weekly for first month, then monthly thereafter
- B. Lithium levels at 12 hours post-dose weekly until stable, then every 3 months with 6-monthly renal and thyroid function (Correct Answer)
- C. Lithium levels and full blood count monthly for first year
- D. Lithium levels daily for first week, then weekly for 3 months
- E. Lithium levels every 6 months with annual renal function tests
Explanation: ***Lithium levels at 12 hours post-dose weekly until stable, then every 3 months with 6-monthly renal and thyroid function***- Serum **lithium levels** should be measured **12 hours post-dose** to ensure they fall within the narrow therapeutic range of **0.4 to 1.0 mmol/L**, with weekly checks initially until stability.- Routine monitoring requires **renal function (eGFR)** and **thyroid function tests (TFTs)** every **6 months** due to risks of nephrotoxicity and hypothyroidism.*Lithium levels weekly for first month, then monthly thereafter*- Weekly checks are appropriate until the dose is **stabilized**, but monthly thereafter is too frequent for stable maintenance and omits vital organ function tests.- For stable patients, monitoring intervals extend to every **3 months**, not monthly, and must include **renal and thyroid** function.*Lithium levels and full blood count monthly for first year*- A **full blood count (FBC)** is not a routine requirement for lithium monitoring; this test is generally associated with other psychotropic medications.- Monthly lithium levels are more frequent than required for a stable patient, and this option critically misses essential **renal and thyroid** function checks.*Lithium levels daily for first week, then weekly for 3 months*- **Daily lithium monitoring** is typically reserved for managing acute **lithium toxicity** or complex inpatient titration, not routine initiation.- Weekly monitoring for 3 months is excessive if a **stable serum level** is achieved earlier, and this schedule omits critical **renal and thyroid** monitoring.*Lithium levels every 6 months with annual renal function tests*- Monitoring lithium levels every **6 months** is only considered for very stable patients after the **first year** of treatment.- **Annual renal function** tests are inadequate, as lithium can cause **nephrogenic diabetes insipidus** and progressive renal decline, requiring at least **bi-annual** checks.
Question 236: A 34-year-old woman with type 1 diabetes is 10 weeks pregnant. She is currently on a basal-bolus insulin regimen with insulin glargine 20 units at night and insulin aspart with meals. Her HbA1c is 7.8% (62mmol/mol). What is the most appropriate modification to her diabetes management?
- A. Switch to oral hypoglycemic agents as insulin crosses the placenta
- B. Increase insulin doses to aim for pre-meal glucose 3.5-5.9mmol/L and 1-hour post-meal <7.8mmol/L (Correct Answer)
- C. Reduce insulin doses by 50% to minimize risk of hypoglycemia
- D. Switch to twice-daily mixed insulin for simplicity
- E. Continue current regimen as HbA1c is acceptable in pregnancy
Explanation: ***Increase insulin doses to aim for pre-meal glucose 3.5-5.9mmol/L and 1-hour post-meal <7.8mmol/L*** - In pregnancy, **glycemic targets** are very strict to reduce the risk of **macrosomia**, congenital anomalies, and neonatal complications; an HbA1c of 7.8% is above the recommended target of **<6.5% (48 mmol/mol)**. - According to **NICE guidelines**, patients should aim for fasting/pre-meal levels between **3.5–5.3 mmol/L** and 1-hour post-meal levels **<7.8 mmol/L** to ensure optimal fetal outcomes. *Switch to oral hypoglycemic agents as insulin crosses the placenta* - **Type 1 diabetes** specifically requires **insulin therapy** because of absolute insulin deficiency; oral agents cannot replace insulin in these patients. - Most insulin formulations do **not cross the placenta** in significant amounts and are the safe, preferred treatment during pregnancy. *Reduce insulin doses by 50% to minimize risk of hypoglycemia* - Reducing doses would lead to **hyperglycemia**, which significantly increases the risk of **fetal malformations** and obstetric complications. - While the risk of **hypoglycemia** is higher in the first trimester, management involves frequent monitoring rather than prophylactic large-scale dose reductions. *Switch to twice-daily mixed insulin for simplicity* - **Mixed insulin** regimens are less flexible and make it difficult to achieve the precise **tight glycemic control** required in pregnancy. - A **basal-bolus regimen** is preferred as it allows for specific adjustments of mealtime (aspart) and background (glargine) insulin to meet changing metabolic demands. *Continue current regimen as HbA1c is acceptable in pregnancy* - An HbA1c of **7.8% (62 mmol/mol)** is considered high for pregnancy and is associated with increased risks of **preeclampsia** and adverse neonatal outcomes. - Treatment must be **intensified** immediately to bring the glucose levels into the target range as the pregnancy progresses into the second trimester.
Question 237: A 58-year-old man is started on direct oral anticoagulant (DOAC) therapy following a diagnosis of atrial fibrillation. His CHA₂DS₂-VASc score is 3. He has normal renal function (eGFR 78ml/min/1.73m²) and normal liver function. Which of the following statements about DOAC monitoring is correct?
- A. INR monitoring is required monthly while on apixaban
- B. Renal function should be checked at least annually (Correct Answer)
- C. Full blood count monitoring is required every 3 months
- D. Liver function tests are only needed if symptoms develop
- E. Anti-Xa levels should be checked before each dose adjustment
Explanation: ***Renal function should be checked at least annually*** - For patients on **Direct Oral Anticoagulants (DOACs)** with a stable **eGFR >60 ml/min**, clinical guidelines recommend monitoring renal function at least **once every 12 months**. - More frequent monitoring is necessary if renal function declines, as DOAC clearance is heavily dependent on **renal excretion**, increasing the risk of toxicity. *INR monitoring is required monthly while on apixaban* - Unlike warfarin, DOACs like **apixaban** have a predictable effect and do not require **INR monitoring** or regular titration. - Using **INR** to monitor DOACs is clinically inappropriate as these drugs do not affect the **International Normalized Ratio** in a consistent or reliable way. *Full blood count monitoring is required every 3 months* - While a baseline **Full Blood Count (FBC)** is essential to screen for anemia, routine **three-monthly monitoring** is not a standard requirement for stable patients. - FBC is typically repeated **annually** or if clinical signs of **occult bleeding** or procedural needs arise. *Liver function tests are only needed if symptoms develop* - Guidelines state that **Liver Function Tests (LFTs)** should be checked at **baseline** and then at least **annually** for patients on chronic DOAC therapy. - Many DOACs, particularly **rivaroxaban** and **apixaban**, undergo significant **hepatic metabolism**, making regular assessment of liver health necessary for safe prescribing. *Anti-Xa levels should be checked before each dose adjustment* - **Anti-Xa assays** are not used for routine dose adjustments; dosing for DOACs is strictly based on clinical criteria like **age, weight, and creatinine clearance**. - Measurement of drug levels is reserved for **emergency situations**, such as major bleeding, suspected overdose, or before **urgent surgery**.
Question 238: A 55-year-old woman with rheumatoid arthritis on methotrexate 15mg weekly presents to the emergency department with a 3-day history of mouth ulcers, sore throat, and fever. Her full blood count shows: Hb 118g/L, WCC 1.2×10⁹/L, neutrophils 0.3×10⁹/L, platelets 245×10⁹/L. What is the most critical immediate action?
- A. Prescribe oral folinic acid 15mg daily for 3 days
- B. Stop methotrexate permanently and avoid restarting
- C. Stop methotrexate and start broad-spectrum antibiotics immediately (Correct Answer)
- D. Reduce methotrexate dose to 10mg weekly and continue monitoring
- E. Continue methotrexate but add prophylactic co-trimoxazole
Explanation: ***Stop methotrexate and start broad-spectrum antibiotics immediately***- The patient presents with **febrile neutropenia**, characterized by a **neutrophil count of 0.3×10⁹/L** and fever, a critical and life-threatening complication of **methotrexate-induced myelosuppression**.- The most urgent immediate action is to stop the causative drug and initiate **empiric intravenous broad-spectrum antibiotics** promptly to manage the severe infection risk and prevent rapid clinical deterioration.*Prescribe oral folinic acid 15mg daily for 3 days*- **Folinic acid** is used as a rescue therapy to mitigate methotrexate toxicity by replenishing folate stores, but it does not address the immediate life-threatening **risk of sepsis**.- While important as an adjunctive measure, administering **broad-spectrum antibiotics** to treat the underlying infection takes precedence in the acute management of **febrile neutropenia**.*Stop methotrexate permanently and avoid restarting*- While methotrexate must be stopped immediately due to severe toxicity, **permanent discontinuation** is not always necessary and depends on the resolution of toxicity and assessment of precipitating factors.- A specialist may consider re-challenging with a lower dose or switching to another DMARD after full **bone marrow recovery** and careful risk assessment.*Reduce methotrexate dose to 10mg weekly and continue monitoring*- Continuing methotrexate, even at a reduced dose, is dangerously inappropriate in the presence of **severe myelosuppression** and active infection like **febrile neutropenia**.- Any evidence of **significant neutropenia** requires immediate cessation of the drug until the **full blood count** normalizes and the patient's condition stabilizes.*Continue methotrexate but add prophylactic co-trimoxazole*- Continuing methotrexate is contraindicated given the patient's severe myelosuppression and signs of infection.- **Co-trimoxazole** is known to increase methotrexate toxicity by displacing it from protein binding and decreasing its renal excretion, which would severely worsen the current **myelosuppression** rather than help.
Question 239: A 72-year-old man is started on digoxin for rate control in atrial fibrillation. Which of the following factors would require a dose reduction of digoxin?
- A. Body weight of 95kg
- B. eGFR of 35ml/min/1.73m² (Correct Answer)
- C. Concurrent use of bisoprolol
- D. History of hypertension
- E. Age over 70 years alone
Explanation: ***eGFR of 35ml/min/1.73m²*** - **Digoxin** is primarily excreted by the **kidneys**; therefore, patients with **renal impairment** (eGFR < 50ml/min) require a dose reduction to avoid accumulation and toxicity. - An eGFR of 35ml/min/1.73m² (CKD stage 3b) significantly increases the risk of **digitalis toxicity**, which can result in life-threatening **arrhythmias**, nausea, and visual changes. *Body weight of 95kg* - Digoxin has a large **volume of distribution** and primarily distributes to **lean muscle mass**, so a higher total body weight does not typically necessitate a dose reduction. - Dose adjustments are usually only considered for patients with a very **low body mass** (e.g., <50kg) to avoid high serum concentrations. *Concurrent use of bisoprolol* - While both drugs have **negative chronotropic** effects and offer additive **rate control**, bisoprolol does not alter the **pharmacokinetics** (metabolism or excretion) of digoxin. - **Drug-drug interactions** that would require dose reduction include those with **amiodarone**, verapamil, or quinidine, which increase digoxin plasma levels. *History of hypertension* - Hypertension is a common comorbidity in patients with **atrial fibrillation** but does not independently affect the **clearance** or mechanism of action of digoxin. - Dosing is primarily driven by **renal function** and serum electrolyte levels (e.g., potassium) rather than blood pressure status. *Age over 70 years alone* - While **elderly patients** often have lower renal reserves, age alone is not a definitive indication for dose reduction if the **renal function** is otherwise normal. - Dosing should be based on a calculated **creatinine clearance** or eGFR rather than age as a stand-alone factor.
Question 240: A 45-year-old woman with type 1 diabetes mellitus is admitted with diabetic ketoacidosis. After initial resuscitation with intravenous fluids and insulin infusion, her blood glucose drops from 28mmol/L to 14mmol/L within 2 hours. Her pH is 7.18 and ketones remain elevated at 4.2mmol/L. What is the most appropriate next step in insulin management?
- A. Stop the insulin infusion until ketones normalize
- B. Reduce the insulin infusion rate by half and continue monitoring
- C. Continue the insulin infusion at the same rate and add 10% glucose (Correct Answer)
- D. Switch from intravenous to subcutaneous insulin immediately
- E. Increase the insulin infusion rate to clear ketones more rapidly
Explanation: ***Continue the insulin infusion at the same rate and add 10% glucose***- In **Diabetic Ketoacidosis (DKA)**, the primary goal is the suppression of ketogenesis and correction of acidosis; insulin must be maintained to achieve **ketone clearance** even if glucose levels drop.- When blood glucose falls below **14 mmol/L**, 10% glucose should be started to prevent **hypoglycemia** while the fixed-rate insulin continues to treat the underlying ketosis.*Stop the insulin infusion until ketones normalize*- Stopping insulin represents a critical error as it allows **ketogenesis** to resume, worsening the metabolic acidosis.- High **ketone levels (4.2 mmol/L)** and low **pH (7.18)** indicate the DKA is not yet resolved, necessitating continuous insulin therapy.*Reduce the insulin infusion rate by half and continue monitoring*- Fixed-rate intravenous insulin infusion (FRIII) should generally be maintained at **0.1 units/kg/hour** to ensure adequate suppression of ketone production.- Reducing the rate prematurely can delay the resolution of **acidosis** and lead to a rebound in ketone levels.*Switch from intravenous to subcutaneous insulin immediately*- The criteria for switching to **subcutaneous insulin** include a pH >7.3, bicarbonate >15 mmol/L, and ketones <0.6 mmol/L, none of which are met here.- Switching before **DKA resolution** can lead to a rapid relapse into ketoacidosis due to the short half-life of IV insulin.*Increase the insulin infusion rate to clear ketones more rapidly*- The insulin rate is typically fixed based on weight; increasing it beyond the standard protocol increases the risk of **cerebral edema** and severe **hypokalemia**.- Rapid shifts in **osmolarity** should be avoided; adding glucose is the standard method to allow continued insulin action safely.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free